其中，兰考第一医院于今年3月份顺利通过三级综合医院执业校验评审，医院管理水平和医疗服务质量 进一步提升。泗阳医院于5月份由二级甲等综合医院成功晋升为三级综合医院，成为泗阳当地唯一的三 级综合医院。盱眙中医院于6月份接受了江苏省中医药管理局组织的省三级中医医院评审委员会进行的 三级中医医院定等评审工作，在建设三级乙等医院上取得重要进展。 此外，新里程在上半年聚焦智慧医疗技术前沿动态，持续追踪人工智能、脑机接口等创新技术在医疗领 域的应用突破。公司通过构建线上线下融合的互联网医疗服务体系，推进人工智能技术的深度应用，以 新质生产力驱动诊疗效率与质量提升，加速打造数字化、智慧化、精准化的医疗与养老产业新生态。 本报讯 （记者刘欢）8月25日晚间，新里程健康科技集团股份有限公司（以下简称"新里程"）发布2025 年半年度报告。公司上半年实现营业收入15.88亿元，归属于上市公司股东的净利润743.11万元。 新里程是一家涵盖医疗服务、药品制造等业务领域的医疗健康产业集团，依据自身业务实际及行业特 性，公司明确制定了高质量发展目标，并进一步深化了"医疗+医药"双轮驱动战略。医疗服务方面，聚 焦于"综合医院本部+肿瘤专科 ...

Group 1 - The core viewpoint of the articles indicates that New Mile's stock closed at 2.25 yuan, down 2.17%, with a rolling PE ratio of 67.98 times and a total market value of 7.622 billion yuan [1] - In terms of industry PE ratio rankings, the average PE for the medical services industry is 47.44 times, with a median of 57.24 times, placing New Mile at the 33rd position [1] - On July 25, New Mile experienced a net inflow of main funds amounting to 9.995 million yuan, showing an overall inflow trend over the past five days, totaling 4.9772 million yuan [1] Group 2 - New Mile Health Technology Group Co., Ltd. specializes in medical services and pharmaceutical manufacturing, focusing on drug production for over 20 years [1] - The company's main products include pharmaceuticals and medical products, with the "Duyiwei" brand being a core series of traditional Chinese medicine, recognized in the 2020 edition of the Chinese Pharmacopoeia [1] - The latest performance report for Q1 2025 shows that the company achieved an operating income of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.6519 million yuan, down 9.35%, with a gross sales margin of 27.96% [1]

Company Overview - New Mile Health Technology Group Co., Ltd. focuses on medical services and pharmaceutical industry, with a primary product line including drugs and medical products [1] - The company has over 20 years of experience in drug production, establishing a series of traditional Chinese medicine centered around the "Duyiwei" brand, which is recognized in the 2020 edition of the "Chinese Pharmacopoeia" [1] Financial Performance - As of the first quarter of 2025, the company reported revenue of 796 million yuan, a year-on-year decrease of 16.49% [1] - The net profit for the same period was 25.65 million yuan, reflecting a year-on-year decline of 9.35% [1] - The sales gross margin stood at 27.96% [1] Market Position - The company's stock closed at 2.19 yuan, with a rise of 1.86%, resulting in a rolling price-to-earnings (PE) ratio of 66.17 times [1] - The total market capitalization of the company is 7.418 billion yuan [1] - In comparison to the medical services industry, which has an average PE of 43.60 times and a median of 46.78 times, New Mile ranks 34th in terms of PE ratio [2] Shareholding Structure - As of the first quarter of 2025, seven institutions hold shares in New Mile, including five other entities, one brokerage, and one fund, with a total holding of 1.3909269 billion shares valued at 3.436 billion yuan [1]

Group 1 - The core viewpoint of the article highlights the performance and market position of New Mile Health Technology Group Co., Ltd, which operates in the medical services and pharmaceutical industry [1] - As of July 8, the closing price of New Mile was 2.14 yuan, reflecting a 2.39% increase, with a rolling PE ratio of 64.65 times and a total market capitalization of 7.249 billion yuan [1] - The average PE ratio for the medical services industry is 42.77 times, with a median of 47.19 times, positioning New Mile at the 34th rank within the industry [1][2] Group 2 - In terms of capital flow, on July 8, New Mile experienced a net outflow of 5.392 million yuan, continuing a trend of outflows over the past five days, totaling 127.0872 million yuan [1] - The company has been focused on pharmaceutical production for over 20 years, with its main products including traditional Chinese medicine, particularly the "Duyiwei" brand, which is recognized in the 2020 edition of the Chinese Pharmacopoeia [1] - The latest financial results for Q1 2025 show that New Mile achieved a revenue of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.652 million yuan, down 9.35%, with a gross profit margin of 27.96% [1]

Core Viewpoint - The company, New Mile Health Technology Group Co., Ltd., has achieved significant growth in revenue and profit in 2024, driven by strategic restructuring, resource integration, and technological innovation in the healthcare sector [1][3]. Group 1: Financial Performance - In 2024, the company reported a revenue of 3.799 billion yuan and a net profit attributable to shareholders of 115 million yuan, marking a substantial year-on-year increase of 296.13% [1]. Group 2: Healthcare Services Development - The company is addressing the uneven distribution of medical resources in China by expanding its healthcare services through strategic restructuring and scale expansion, focusing on regional medical needs [3]. - Key hospitals under the company, such as Siyang Hospital and Lankao First Hospital, are enhancing their specialized capabilities and optimizing their discipline layout to improve patient care [3]. - The company has successfully created a virtuous cycle of "scale expansion - quality improvement - efficiency growth" by enhancing operational efficiency and cost control, leading to increased market share and patient satisfaction [3]. Group 3: Pharmaceutical Manufacturing - With over 20 years in pharmaceutical manufacturing, the company has established a competitive advantage in the traditional Chinese medicine sector, centered around its core product, "Duyiwei Capsule" [3]. - The "Duyiwei Capsule" has been recognized for its unique efficacy, high safety, and low treatment costs, being included in the Chinese Pharmacopoeia and various national medical insurance directories [3]. Group 4: Marketing and Brand Development - The company has developed a dual-driven marketing model of "distribution + specialized academic promotion," investing in academic promotion for nearly a decade to build a stable sales team [4]. - The "Duyiwei" trademark was awarded "China Famous Trademark" in 2024, further solidifying its market position [4]. Group 5: Industry Trends and Future Outlook - The healthcare industry in China is experiencing favorable conditions due to an aging population and increasing chronic disease prevalence, with over 260 million chronic disease patients [4]. - The company plans to continue focusing on its dual main businesses of "healthcare + pharmaceuticals," enhancing regional medical center construction and increasing investment in innovative drug research and development [4].

Company Overview - New Mile Health Technology Group Co., Ltd. focuses on medical services and pharmaceutical industry, with a primary product line that includes medicines and medical products [1] - The company has over 20 years of experience in drug production, establishing a series of traditional Chinese medicine centered around the "Duyiwei" brand, which is recognized in the 2020 edition of the "Chinese Pharmacopoeia" [1] Financial Performance - For Q1 2025, the company reported a revenue of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.65 million yuan, down 9.35% year-on-year, with a gross margin of 27.96% [1] - The current stock price is 2.17 yuan, reflecting a decline of 1.36%, with a rolling price-to-earnings (PE) ratio of 65.56 times [1] Market Position - The average PE ratio for the medical services industry is 41.66 times, with a median of 43.26 times, positioning New Mile at 34th place within the industry [2] - The company's total market capitalization is 7.351 billion yuan [2] Shareholder Information - As of June 10, 2025, New Mile has 64,494 shareholders, an increase of 419 since the last report, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of New Mile Health Technology Group Co., Ltd, indicating a decline in revenue and net profit in the latest quarterly report [1][2] - As of June 30, the closing price of New Mile was 2.2 yuan, down 1.79%, with a rolling PE ratio of 66.47 times and a total market value of 7.452 billion yuan [1] - The company operates in the medical services and pharmaceutical industry, focusing on drug production for over 20 years, with its main product being the "Duyiwei" series of traditional Chinese medicine [1] Group 2 - The average PE ratio for the medical services industry is 41.55 times, with a median of 42.46 times, positioning New Mile at 34th place among its peers [2] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.65 million yuan, down 9.35% year-on-year, with a gross profit margin of 27.96% [1]

Core Insights - The company reported a significant increase in cash flow for 2024, with a notable rise in net profit, while Q1 2025 performance faced slight pressure [1][2] Financial Performance - In 2024, the company achieved operating revenue of 3.799 billion, a year-on-year decrease of 2.95%, and a net profit attributable to shareholders of 115 million, a year-on-year increase of 296.13% [1] - The operating cash flow for 2024 increased by 36.64% to 439 million [2] - For Q1 2025, the company reported operating revenue of 796 million, a year-on-year decrease of 16.49%, and a net profit attributable to shareholders of 26 million, a year-on-year decrease of 9.35% [2] Cost Management - In 2024, the company optimized management expenses, with a sales expense ratio of 7.75%, up 2.07 percentage points year-on-year, and a management expense ratio of 13.70%, down 3.43 percentage points year-on-year [2] - The overall expense ratio remained stable in Q1 2025, with a gross margin of 27.96%, down 0.84 percentage points year-on-year [2] Healthcare Services Expansion - The company is expanding its healthcare services with new bed releases, including the opening of 300 beds at the Siyan Hospital East District and the upcoming opening of new facilities at other hospitals [3] - The healthcare services segment generated operating revenue of 3.036 billion in 2024, a year-on-year decrease of 2.68% [2][3] Pharmaceutical and Medical Products - The pharmaceutical and medical products segment achieved operating revenue of 753 million in 2024, a year-on-year decrease of 3.82%, with a gross margin of 49.48%, up 5.52 percentage points [4] - The company has strengthened its market position with its "Duyiwei" series of products, which successfully participated in national procurement [4][5] Strategic Initiatives - The company is extending its industrial chain through acquisitions, such as the purchase of Gansu Furen Pharmaceutical, to create a complete cycle from planting to processing and sales of traditional Chinese medicine [5] - The company is also diversifying into consumer healthcare with new product lines in oral care and health foods [6] Network and Infrastructure - By the end of 2024, the company had established a medical network covering six major regions, with a total of 24 medical institutions [6] - The company is implementing a "1+N" medical service model to enhance its regional medical center construction [6] Investment Outlook - Despite slight pressure on Q1 performance, the company anticipates gradual improvement in performance with the continued release of new beds, adjusting revenue and net profit forecasts for 2025-2026 [7]